Hypotensive function of the brain angiotensin-(1-7) in Sprague Dawley and renin transgenic rats.
Angiotensin-(1-7) (Ang-[1-7]) is present in the brain of normotensive Sprague Dawley (SD) rats, and its hypothalamic content is elevated in TGRmRen2(27) rats (TGR) with renin dependent transgenic hypertension. The purpose of the present study was to determine the role of intrabrain Ang-(1-7) in the regulation of cardiovascular functions in SD and TGR rats under resting conditions and during haemodynamic challenge produced by rapid bleeding. Two groups of experiments were performed on conscious SD and TGR rats that were chronically instrumented with a lateral cerebral ventricle (LCV) cannula and an intraarterial catheter. Blood pressure (MAP) and heart rate period (Hp=distance between two systolic peaks) were continuously monitored: 1) under resting conditions during an LCV infusion of either artificial cerebrospinal fluid (aCSF, 5 microl/hr) or Ang-(1-7) in aCSF (100 pmol/5 microl/hr), and 2) before and after haemorrhage performed during LCV infusion of either aCSF or Ang-(1-7) antagonist (A-779, 4 nmol/5 microl/hr). Cerebroventricular infusion of Ang-(1-7) did not affect baseline MAP in the SD rats but it caused a significant decrease in blood pressure in the TGR rats. In the control experiments, haemorrhage significantly reduced MAP in the SD and TGR rats and heart rate in the TGR rats. Cerebroventricular infusion of Ang-(1-7) antagonist eliminated posthaemorrhagic hypotension in both strains and bradycardia in the TGR rats. The results indicate that intrabrain Ang-(1-7) may contribute to posthaemorrhagic hypotension and bradycardia. Moreover, the manner in which it centrally regulates the cardiovascular functions in the SD and TGR rats may be considerably different.
Dobruch
J
J
Department of Experimental and Clinical Physiology, Medical University of Warsaw, Warsaw, Poland.
Paczwa
P
P
Łoń
S
S
Khosla
M C
MC
Szczepańska-Sadowska
E
E
D000222:Adaptation, Physiological; D000803:Angiotensin I / Q000737:chemistry* / Q000494:pharmacology / Q000502:physiology*; D000804:Angiotensin II / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D030801:Animals, Genetically Modified / Q000502:physiology*; D001794:Blood Pressure / Q000187:drug effects; D002552:Cerebral Ventricles / Q000187:drug effects; D002555:Cerebrospinal Fluid / Q000737:chemistry / Q000378:metabolism; D006339:Heart Rate / Q000187:drug effects; D006470:Hemorrhage / Q000150:complications / Q000503:physiopathology; D006973:Hypertension / Q000209:etiology / Q000235:genetics; D007022:Hypotension / Q000150:complications / Q000503:physiopathology*; D007031:Hypothalamus / Q000737:chemistry* / Q000502:physiology; D007276:Injections, Intraventricular; D010446:Peptide Fragments / Q000737:chemistry* / Q000494:pharmacology / Q000502:physiology*; D051381:Rats / Q000235:genetics*; D017207:Rats, Sprague-Dawley; D012083:Renin / Q000097:blood / Q000235:genetics / Q000502:physiology*; D012771:Shock, Hemorrhagic / Q000150:complications / Q000503:physiopathology / Q000517:prevention & control; D013045:Species Specificity
C092006:7-Ala-angiotensin (1-7); D010446:Peptide Fragments; D000804:Angiotensin II; D000803:Angiotensin I; D012083:Renin; C118790:angiotensin I (1-7)